Close Menu

NEW YORK (GenomeWeb) – Bio-Rad Laboratories will collaborate with Genetic Analysis and Bioaster, a French microbiology research institute, to study gut microbiome alterations in metabolic disorders, Bioaster announced today.

The project will look for microbiota signatures of dysbiosis in metabolic disorders like diabetes and obesity in order to pursue diagnostics development. It will use Bioaster's deep and 16S-targeted sequencing technologies and advanced pipelines of data analysis for highlighting new gut microbiome biomarkers, according to a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.